Brief: Biotec Pharmacon says Woulgan will be listed on UK Drug Tariff
19/10/2017 18:47
Oct 19 (Reuters) - Biotec Pharmacon ASA BIOTEC.OL
* Says its wholly owned subsidiary Biotec BetaGlucans
received feedback from NHS that Woulgan, a wound treatment
product, will be listed on UK Drug Tariff from January 2018
* Says will focus its efforts on a successful launch in
January 2018
* Says seeks to establish a portfolio of advanced wound care
products based on the company's proprietary beta-glucan
technology
Source text for Eikon: ID:nObi0smzya
Further company coverage: BIOTEC.OL
((nerijus.adomaitis@thomsonreuters.com;))